HIGH
CVE-2022-45792
CWE-22Published: January 22, 2024· Updated: Jun 17, 2026
7.8
CVSS v3.1
Official Description
Project files may contain malicious contents which the software will use to create files on the filesystem. This allows directory traversal and overwriting files with the privileges of the logged-in user.
Technical Analysis
CVE-2022-45792 requires local access, meaning attackers must already have a foothold on the target system.
Exploitation does not require any privileges, though user interaction (Required) is needed, which slightly reduces the risk of mass automated attacks.
A successful exploit results in complete confidentiality breach (data exposure), full integrity compromise (data manipulation), availability disruption (denial of service), with a CVSS base score of 7.8.
CVSS v3.1 Vector Breakdown
Exploitability
Attack VectorLocal
Attack ComplexityLow
Privileges Req.None
User InteractionRequired
ScopeUnchanged
Impact
ConfidentialityHigh
IntegrityHigh
AvailabilityHigh
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
Affected Vendors & Products
omron1 product(s)
sysmac studio
Source: NVD CPE · 1 total CPE entries
Exploit & PoC Resources
NO KNOWN EXPLOITNo public exploit confirmed at this time
Exploit-DB
Offensive Security exploit database
GitHub PoC Search
Community PoC repositories
Rapid7 / Metasploit
Metasploit module search
PacketStorm
Security advisories & exploits
NVD Detail
Official NIST entry
MITRE CVE
CVE Program entry
External links open in a new tab. Always verify in a controlled environment before use.
Official Patches & Advisories
All References (2)
Quick Facts
CVE IDCVE-2022-45792
CVSS Score7.8 / 10
SeverityHIGH
WeaknessCWE-22
CISA KEVNo
Affected1 vendor(s)
PublishedJan 22, 2024
Related CVEs (CWE-22)
Recommended Actions
- →Apply vendor patches immediately
- →Monitor CVE-2022-45792 in threat intel feeds
- →Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.